title: Long-term results of the S.M.A.R.T. Control(TM) stent for superficial femoral artery lesions, J-SMART registry.
abstract: BACKGROUND
  The use of a stent in the treatment of lesions of the superficial femoral artery (SFA) remains controversial. Although some reports have suggested that use of a nitinol stent in conjunction with aggressive medical management is effective for long SFA lesions, few long-term, large-scale studies have been done.
  
  
  RESULTS
  A retrospective analysis was conducted of data from a multicenter study in which the S.M.A.R.T. Control(TM) stent was used for treatment of de novo SFA lesions. A total of 528 lesions in 432 patients were included. Mean patient age was 72.5±9.1 years; mean stent length was 15.7±8.1cm; 259 lesions (49%) were classified as C/D according to the TransAtlantic Inter-Society Consensus (TASC) II classification. Primary and secondary patency at 4 years was 66% and 87%, respectively. No cilostazol administration (41% re-stenosis group vs. 29% no-restenosis group, P<0.01), female gender (42% vs. 26%, P<0.01), younger age (70.7±9.3 years vs. 72.9±9.0 years, P<0.05), and chronic total occlusion (CTO; 72% vs. 52%, P<0.01) were independent predictors of re-stenosis.
  
  
  CONCLUSIONS
  The S.M.A.R.T. Control(TM) stent provided good long-term durability in the treatment of SFA lesions, and no cilostazol administration, female gender, younger age and CTO were associated with re-stenosis.
authors.affiliation: Sendai Kousei Hospital, Cardiovascular Center, Sendai 980-0873, Japan. k-y.suzuki@nifty.com
authors.forename: Kenji
authors.initials: K
authors.lastname: Suzuki
authors.forename: Osamu
authors.initials: O
authors.lastname: Iida
authors.forename: Yoshimitsu
authors.initials: Y
authors.lastname: Soga
authors.forename: Keisuke
authors.initials: K
authors.lastname: Hirano
authors.forename: Naoto
authors.initials: N
authors.lastname: Inoue
authors.forename: Masaaki
authors.initials: M
authors.lastname: Uematsu
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Yokoi
authors.forename: Toshiya
authors.initials: T
authors.lastname: Muramatsu
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Nanto
authors.forename: Masakiyo
authors.initials: M
authors.lastname: Nobuyoshi
authors.forename: Taiichiro
authors.initials: T
authors.lastname: Meguro
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000077407:Cilostazol; D005260:Female; D005263:Femoral Artery; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D058729:Peripheral Arterial Disease / Q000628:therapy*; D012042:Registries; D015607:Stents; D013777:Tetrazoles / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D013777:Tetrazoles; D014665:Vasodilator Agents; D000077407:Cilostazol